<ul><li>The US Court ruling in the Myrbetriq patent case has led Systematix to retain a hold rating on shares of Zydus and Lupin.</li><li>Systematix has also cut the target price due to the court ruling which blocks the sale of generic versions of Myrbetriq in the US until the patent expires in March 2030.</li><li>Lupin and Zydus Life had filed ANDAs with the USFDA to market generic versions of Myrbetriq, but their plans have been halted by the court ruling.</li><li>The patent challenge made by Lupin and Zydus Life was rejected by the US District Court for the District of Delaware.</li></ul>

Zydus, Lupin Shares: Systematix Retains Hold, Cuts Target Price Over US Court Ruling In Myrbetriq Patent Case

Discover more